The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.

September 16, 2021 updated by: Dr. Michelle Murphy, Institut Investigacio Sanitaria Pere Virgili

Phase 1 Study of the Effect of Maternal Nutritional Status on Placental Vascular Function, Fetal Growth and Intrauterine Growth Retardation.

The recent fall in birth and death rates has led to demographic changes such as low fertility and high life expectancy . The WHO reports the median age of the European population to be the highest in the world and predicts that the proportion of over-60s in will increase from 14% in 2010 to 25% in 2050. There is wide variability in the quality of health and well-being in the ageing population. Longevity with a good quality of life is a consequence of the combination of an individual's genes, nutrition, environment, lifestyle and medical interventions. There is increasing evidence that research into healthy ageing needs to start with early life data to capture all traits and exposures experienced by an individual throughout life. Epigenetic imprinting occurs both in utero and during early postnatal development. Maternal environmental exposures, including nutritional status, may have a permanent effect on the developing foetus by influencing epigenetic profiles and leading to life-long genome adaptation. Numerous reports show that restricted intra-uterine growth due to poor maternal nutrition during pregnancy increases risk in the offspring of developing mental disorders, metabolic syndrome, cardiovascular disease or stroke in later life. To understand the basic mechanisms and interactions through which the ageing phenotype develops, systems involved in key processes of early development must be considered as well as those crucial to health in older persons. The Reus and Tarragona Birth Cohort is a longitudinal study. In the first phase, blood is collected from pregnant women at <12, 15, 24-27 and 34 gestational weeks (GW) and at labor and from the cord. Detailed lifestyle, habits and supplement use data are collected at 20 and 32 gestational weeks and on nutritional habits at <12GW and at birth. Placental vascular function is assessed at 20 and 32 GW by analysis of Doppler waveforms of the uterine arteries. Data on pregnancy evolution and outcome are also recorded. The first phase investigates the association between gene-environment (nutrient and lifestyle habits) interactions and fetal growth and pregnancy outcome. The second phase of the study follows up the children at 7.5 years of age. Growth, exercise and nutritional habits as well as environment and cognitive development are assessed. The aims are to investigate the association between gene-environment interactions associated with healthy development from early pregnancy until 7.5 years of age.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

831

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tarragona, Spain, 43005
        • Hospital de Tarragona Joan XXIII
    • Tarragona
      • Reus, Tarragona, Spain, 43201
        • Hospital Universitari Sant Joan de Reus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women less than 12 weeks pregnant at their first pre-natal check up are recruited from the URV University Hospitals: Sant Joan (Reus) and Joan XXIII (Tarragona)

Description

Inclusion Criteria:

  • <12 weeks pregnant at first prenatal check up

Exclusion Criteria:

  • Illnesses / interventions affecting nutritional status, major recent surgery in the previous 6 months, multiple pregnancies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pregnant women
Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Birth weight
Time Frame: At birth
At birth
Doppler waveforms of uterine arteries
Time Frame: 20 gestational weeks
20 gestational weeks

Other Outcome Measures

Outcome Measure
Time Frame
1-C metabolites
Time Frame: <12, 15, 24-27, 34 gestational weeks, at labor, in the cord
<12, 15, 24-27, 34 gestational weeks, at labor, in the cord
Intrauterine growth retardation
Time Frame: At birth
At birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michelle M Murphy, PhD, Universitat Rovira i Virgili
  • Study Director: Pere Cavallé-Busquets, MD, PHD, Hospital Universitari Sant Joan de Reus
  • Study Chair: Joan D Fernandez-Ballart, PhD, Universitat Rovira i Virgili
  • Study Director: Mónica Ballesteros, MD, PHD, Hospital de Tarragona Joan XXIII

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2005

Primary Completion (Actual)

September 14, 2020

Study Completion (Actual)

September 14, 2020

Study Registration Dates

First Submitted

January 25, 2013

First Submitted That Met QC Criteria

January 25, 2013

First Posted (Estimate)

January 29, 2013

Study Record Updates

Last Update Posted (Actual)

September 23, 2021

Last Update Submitted That Met QC Criteria

September 16, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • IISPV_Murphy1
  • SPAIN MICINN (Other Grant/Funding Number: Ministerio de Ciéncia y Innovación SAF2005/05096)
  • SPAIN ISCIII (Other Grant/Funding Number: Instituto de Salud Carlos III PI19/00844)
  • SPAIN URV (Other Grant/Funding Number: Universitat Rovira i Virgili)
  • SPAIN AEI (Other Grant/Funding Number: Agencia Estatal Investigacion PCI2018-093098)
  • Horizon 2020 (Other Grant/Funding Number: JPI ERA-HDHL Nutrition & The Epigenome)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intrauterine Development

Clinical Trials on Observational

3
Subscribe